Loading...
Loading...
Oppenheimer & Co. is out with a research report on Simcere Pharmaceutical Group
SPAR and it has a Perform rating.
In a note to clients, Oppenheimer & Co. writes, "SCR reported an 8.9% yoy sales decline due to under-performance of Edaravone and "other branded generics" (-20%yoy), caused by pricing pressure and ongoing provincial drug tenders. Edaravone declined 5.3% yoy, while Endu grew nicely at 20% yoy, attributable to improving efficiency of the sales team. EPS of $0.10 missed Street's $0.15 estimate, due to higher selling and R&D expenses caused by lower than expected sales. Meanwhile, A/R days and inventory days increased significantly on both qoq and yoy basis. Management believes long-term volume growth opportunity exists for SCR with improved affordability but believe it will be after several quarters. We lower our 4Q11 revenue/GAAP EPADS estimates to RMB577M/$0.15. Maintain Perform."
Shares of SPAR are off 17 cents to $4.78, a loss of 3.45%.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in